Yes, GLP-1 (glucagon-like peptide-1) increases insulin secretion, and it does so in a uniquely safe way. Unlike some other signals that push the pancreas to release insulin regardless of blood sugar levels, GLP-1 only triggers insulin release when blood glucose is elevated above fasting levels. Once blood sugar drops back to normal, GLP-1’s effect on insulin shuts itself off. This built-in safety mechanism is a major reason why GLP-1-based medications have become central to type 2 diabetes treatment.
How GLP-1 Triggers Insulin Release
GLP-1 is a hormone your gut produces after you eat. It travels through the bloodstream and binds to receptors on beta cells, the insulin-producing cells in your pancreas. When GLP-1 locks onto these receptors, it activates a signaling protein called Gαs, which raises levels of a molecule called cAMP inside the cell. That rise in cAMP is the key event: it causes the beta cell to release stored insulin into your bloodstream.
The insulin response to GLP-1 is proportional to the amount of glucose present. Eat a large carbohydrate-heavy meal and your blood sugar rises sharply, so GLP-1 drives a strong insulin response. Eat a smaller meal and the response is more modest. This proportional, glucose-dependent action means GLP-1 amplifies insulin secretion exactly when your body needs it most, during and after meals, and backs off when it doesn’t.
Why GLP-1 Rarely Causes Low Blood Sugar
The glucose-dependent nature of GLP-1 has a critical practical consequence: it doesn’t push blood sugar below fasting levels. As postmeal blood glucose falls back toward normal, GLP-1’s insulin-boosting effect becomes self-terminating. Even when GLP-1 is given intravenously at high doses, it fails to reduce blood sugar below fasting levels. This is fundamentally different from older diabetes drugs like sulfonylureas, which stimulate insulin release whether blood sugar is high or not.
Real-world data illustrates this difference clearly. In a large study of adults with type 2 diabetes, people taking GLP-1 receptor agonists experienced hypoglycemia at a rate of 1.7 events per 100 person-years, compared to 3.3 events per 100 person-years for those on sulfonylureas. That translates to roughly half the risk. For severe hypoglycemia specifically, GLP-1 receptor agonists cut the risk by 50% compared to sulfonylureas.
GLP-1 Also Suppresses Glucagon
Insulin isn’t the only hormone GLP-1 influences. It also suppresses glucagon, the hormone that tells your liver to release stored sugar into the bloodstream. GLP-1 reduces glucagon secretion by 50 to 70% through receptors on alpha cells in the pancreas. This is a direct effect: GLP-1 activates its receptors on the alpha cell membrane, which leads to inhibition of specific calcium channels that the alpha cell needs to release glucagon.
The combination of more insulin and less glucagon is what makes GLP-1 so effective at lowering blood sugar after meals. Insulin helps your muscles and tissues absorb glucose while the drop in glucagon prevents your liver from dumping additional sugar into the bloodstream at the same time.
GLP-1 Medications and Insulin Doses
For people with type 2 diabetes, GLP-1 receptor agonists (drugs like semaglutide and liraglutide) harness this biology therapeutically. They mimic natural GLP-1 but last much longer in the body. Because they boost your own insulin production in a glucose-dependent way, they can reduce or even eliminate the need for injected insulin in some patients.
The American Diabetes Association’s 2025 guidelines recommend reassessing insulin doses whenever a GLP-1 receptor agonist is started or increased. This is because the added insulin-boosting effect of the GLP-1 drug, layered on top of injected insulin, could tip blood sugar too low. In clinical trials of people with type 1 diabetes taking liraglutide, participants saw modest reductions in A1C (about 0.4%), lost roughly 5 kilograms (11 pounds), and were able to reduce their insulin doses.
When insulin is still needed alongside a GLP-1 drug, the combination is actually preferred. The guidelines specifically recommend pairing insulin with a GLP-1 receptor agonist for better blood sugar control, weight benefits, and lower hypoglycemia risk compared to insulin alone.
Effects on Insulin Sensitivity
Beyond stimulating insulin release, GLP-1 receptor agonists appear to improve how well your body responds to insulin. Some of this improvement comes indirectly through weight loss: as you lose fat, particularly visceral fat around your organs, your cells become more responsive to insulin’s signal. There is also evidence that improved fat tissue function and lipid metabolism contribute to better insulin sensitivity over time.
Newer dual-action drugs like tirzepatide, which activate both GLP-1 and GIP receptors simultaneously, appear even more effective at increasing both insulin secretion and insulin sensitivity compared to GLP-1 receptor agonists alone. Animal studies showed that dual activation reduced fat mass and improved metabolic profiles beyond what selective GLP-1 activation achieved, and clinical trials in humans have confirmed these findings.
Potential Benefits for Beta Cells
In type 2 diabetes, beta cells gradually lose function and die off over time, which is why the disease tends to worsen over the years. GLP-1 appears to counteract this process, at least in animal models. Studies in diabetic mice show that GLP-1 stimulates beta cell replication, promotes the development of new beta cells, and inhibits beta cell death by reducing oxidative stress and other forms of cellular damage. The human GLP-1 analogue liraglutide preserved beta cell populations in these models by regulating cell turnover and suppressing stress pathways.
Whether these protective effects translate fully to humans over the long term remains an open question, but the direction of the evidence is encouraging. Preserving beta cell health could mean that GLP-1 medications don’t just manage blood sugar today but slow the underlying progression of type 2 diabetes.